Obsidian Therapeutics (OBX) Director Matthew Norkunas Receives Award

What Happened
Matthew Norkunas, a director of Obsidian Therapeutics (OBX), was granted a derivative award representing 37,653 shares on August 3, 2026. The Form 4 reports the acquisition as a derivative award at $0.00 (no cash paid / reported value $0). This is a grant of award/option-type securities rather than an open‑market purchase or sale.

Key Details

• Transaction date: 2026-08-03 (Form 4 filed 2026-08-05). Transaction code: A (award/grant).
• Reported terms: 37,653 derivative shares acquired at $0.00 (reported value $0).
• Vesting note: The filing footnote states the shares underlying this option vest and become exercisable on the earlier of (i) the one‑year anniversary of the grant date or (ii) the issuer’s next annual meeting, subject to continued service.
• Shares owned after the transaction: not specified in the summary provided (see the Form 4 for total holdings).
• Timeliness: Filing appears timely (transaction 8/3; filed 8/5), no late‑filing flag indicated.

Context
This was a derivative award (option/award) with time‑based vesting — the securities are not immediately tradable and require vesting (and later exercise if applicable) before converting to common stock. Such grants are common for director compensation; they are not an open‑market purchase or sale and do not necessarily indicate insider buying/selling sentiment. For full specifics (exercise price, plan terms, and post‑grant ownership), review the complete Form 4 filing (Accession: 0001193125-26-335083).